AKT1 and hepatocellular carcinoma: Nearly 50% of patients with HCC have shown the dysregulation of the AKT/mTOR pathway, which may be partially associated with activation signals from receptor tyrosine kinases, such as IGFR and/or EGFR pathways [7].